Sanofi-aventis is one of the world’s leading pharmaceutical companies.

The Group operates in more than 100 countries, with around 100,000 employees. It has approximately 17,600 scientists working in over 28 research centers in three continents to create innovative therapeutic treatments.

Our global headquarters are in Paris, France.

We have leading products across a range of therapeutic areas and we are committed to research and innovation to meet the current and future medical needs. Sanofi-aventis focuses its activities on 7 major therapeutic areas:

• Cardiovascular
• Thrombosis 
• Oncology
• Central Nervous System  
• Metabolic Disorders 
• Internal Medicine  
• Vaccines          

The sanofi-aventis portfolio of marketed products includes several medicines that are world leaders in their respective classes, in the areas of thrombosis, cardiovascular disease, bone disease, sleep disorders, epilepsy, diabetes and cancer. 

With more than 25 research centres on three continents, sanofi-aventis coordinates its Research and Development on a worldwide basis.  The sanofi-aventis annual R&D budget exceeds four billion euros and ranks among the three largest budgets of global pharmaceutical industry. Sanofi-aventis currently possesses one of the richest and most innovative portfolios in the industry with more than 100 molecules and vaccines in development, half of which are in advanced stages (phases II and III).

The mission of sanofi-aventis research: to find truly innovative drugs that provide new therapeutic solutions to patients.


For more information about sanofi-aventis worldwide, visit www.sanofi-aventis.com.